Correspondence 0001493152-24-042399 from Aspire Biopharma Holdings, Inc. (ASBP)
Aspire Biopharma Holdings, Inc.
Date: Oct. 24, 2024 · CIK: 0001847345 · Accession: 0001493152-24-042399
AI Filing Summary & Sentiment
File numbers found in text: 001-41293
Show Raw Text
CORRESP
1
filename1.htm
Dykema
Gossett PLLC
111
E. Kilbourn Ave.
Suite
1050
Milwaukee,
WI 53202
www.dykema.com
Tel:
414-488-7300
Kate
Bechen
Direct
Dial: (414) 488-7333
Email:
KBechen@dykema.com
October 24, 2024
U.S. Securities and Exchange Commission
Division of Corporate Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Eric Atallah and Lynn Dicker
Re: PowerUp
Acquisition Corp.
Form 10-K for Fiscal Year Ended December 31, 2023
Form 10-Q for Fiscal Quarter Ended June 30, 2024
File No. 001-41293
Dear
Mr. Atallah and Ms. Dicker:
This
response letter (this “Response”) is submitted on behalf of PowerUp Acquisition Corp. (the “Company”)
in response to the comment that the Company received from the staff of the Division of Corporation Finance (the “Staff”)
of the U.S. Securities and Exchange Commission (the “SEC”) in a letter addressed to Mr. Doss, dated October 15, 2024
(the “Comment Letter”), with respect to the Company’s annual report filed with the SEC on March 11, 2024 and
quarterly reports filed with the SEC on June 5, 2024 and August 16, 2024 (each a “Quarterly Report”). The Company
is concurrently submitting a first amendment to each Quarterly Report, which reflects the changes discussed in this Response that the
Company made to address the Staff’s comment.
For
reference purposes, the Staff’s numbered comment from the Comment Letter is set forth in bold text below, followed by the Company’s
response to the comment. The responses below are based on information provided to Dykema Gossett PLLC by the Company.
Form
10-Q for Fiscal Quarter Ended June 30, 2024
Item
6. Exhibits, page 27
1. We
note that your officer certifications at Exhibits 31.1 and 31.2 exclude the introductory
language in paragraph 4 and paragraph 4(b) regarding responsibilities for establishing and
maintaining internal control over financial reporting. Please amend your March 31 and June
30, 2024 Forms 10-Q to include certifications having all of the prescribed language as set
forth in Item 601(b)(31)(i) of Regulation S-K. Your amendment may include only the cover
page, explanatory note, signature page and paragraphs 1, 2, 4 and 5 of the certifications.
Response:
In response the Staff’s comments, the Company has filed Amendment No. 1 to the Quarterly Report for the period ended March
31, 2024 and Amendment No.1 to the Quarterly Report for the period ended June 30, 2024 to include in the certifications provided in Exhibits
31.1 and 31.2 to such filings paragraph 4(b) and the introductory language in paragraph 4 referring to internal control over financial
reporting.
*
* *
California | Illinois | Michigan | Minnesota | Texas | Washington, D.C. | Wisconsin
U.S.
Securities and Exchange Commission
Division
of Corporate Finance
October
24, 2024
Page
2
Thank
you for your review and consideration of the matters set forth in this Response and in each amendment to the Quarterly Reports. If you
have any questions, please contact the undersigned at (414) 488-7333 or KBechen@dykema.com.
Sincerely,
Dykema
Gossett PLLC
/s/ Kate Bechen
Kate
Bechen, Esq.
cc: Howard
Doss
Chief
Financial Officer
PowerUp
Acquisition Corp.